Overcome Regulatory, Clinical, Manufacturing & Pricing Bottlenecks to Progress Safer, Efficacious, Accessible Rare Gene Therapies From Early Clinical Development Through to Approval

2022 has been a landmark year for the global gene therapy space. With August came the green light for bluebird bio’s Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Hot off its heels we saw the accelerated approval of another bluebird bio product, Skysona. Overseas, July and August brought EMA approvals for PTC Therapeutics' Upstaza and BioMarin’s Roctavian, the first gene therapies for AADC deficiency and Haemophilia A respectively.

As the gene therapy field continues to break records, there are still significant challenges to overcome relating to safety, efficacy, and accessibility. The 6th Annual Gene Therapy for Rare Disorders 2023 Summit remains devoted to showcasing the top case studies and strategic learnings from the past year. With an expert speaking faculty devoted to bringing safer and more effective gene therapies to rare disease patients, key questions will be answered on how best the field can overcome regulatory, clinical, manufacturing and pricing bottlenecks to progress gene therapies into and through the clinic.

500+ leading experts from innovative biotechs, large pharma, academia and key service providers will be reuniting in Boston for 2023 to capitalize on recent success stories and collaborate over the most pressing industry challenges. An event vital to unlocking the full potential of your rare gene therapy program, join us to keep your finger on the pulse and set up for success in 2023.

Download the 2023 Full Event Guide.

Lead Partner

Advance_stacked_2021_rgb (002)

Expertise Partners

Sartorius-Logo_BIA-separations-Logo_Part-of Sartorius
Azzur
Invitae

Other Events In The Gene Therapy Series